Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.QLT reports positive FDA review of Aczone
The supplemental new drug application (sNDA) submitted at the end of May 2007 was primarily based on the Phase IV clinical trial completed in 56 safety-evaluable glucose-6-phosphate dehydrogenase
The supplemental new drug application (sNDA) submitted at the end of May 2007 was primarily based on the Phase IV clinical trial completed in 56 safety-evaluable glucose-6-phosphate dehydrogenase
A team of scientists at Dynamis significantly decreased kidney and retina Rage in aged rats that were orally dosed with company’s Rage inhibitor for 32 weeks, as compared
The Axxent System which was previously cleared for accelerated treatment of early stage breast cancer is now cleared for use in the treatment of other cancers or conditions
Under the terms of the contract, Aetna Medicare members residing in certain long-term care facilities in New Jersey will receive around-the-clock hands-on care by an on-site ECI nurse
CardioDynamics’s impedance cardiography (ICG) products enable Global Research Services (GRS) to provide expanded biometrics and data management services in support of clinical trials. The combined strengths of both
This is the third generic western medicine to be included in Tianyin’s product portfolio. The company will continue to diversify its traditional Chinese medicine products, with additional western
The operating loss for 2007 was $856,000 compared to operating income of $251,000 in 2006. The company reported a net loss of $990,000, or $0.05 per share, for
The Phase I trial, which is being conducted in the US, is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TC-5214 in healthy volunteers. TC-5214 is
Revenue for the year ended December 31, 2007 was $18.1 million, compared to $28.5 million for the year ended December 31, 2006. Net loss for the three months
This new initiative will focus on accessing large clinical cohorts for validating its diagnostic products through the company’s collaborative network. Lipomics will use its analytical and bioinformatic technology